Hypothesis / aims of study Muscarinic receptor antagonists have long been the mainstay of therapy for patients with overactive bladder. Previously these antagonists were thought to block detrusor muscarinic receptors and inhibit bladder contraction. Surprisingly, clinical trials with the newer antagonists have demonstrated a beneficial effect on the symptom of urgency, a symptom not attributable to detrusor muscarinic receptor activation. Recent studies in humans (1) and animals (2) have indicated that muscarinic receptors are present on both mucosa and detrusor of the urinary bladder. These mucosal muscarinic receptors may represent a novel site of action of antimuscarinic agents.
COMPARISON OF RECEPTOR BINDING CHARACTERISTICS OF COMMONLY USED MUSCARINIC ANTAGONISTS IN HUMAN BLADDER DETRUSOR AND MUCOSA
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Our primary aim was to examine the binding characteristics of three recently developed muscarinic receptor antagonists and compare them to oxybutynin, a widely used muscarinic receptor antagonist. The newer antagonists to be examined were darifenacin (M3 selective), trospium (non-selective) and fesoterodine (M3 preferring), which is currently under development. Our secondary aim was to compare the binding characteristics of these agents in the mucosa compared with the detrusor. 
Results

All antagonists displayed high affinity competition for [
3 H]QNB binding to both detrusor and mucosa membranes. In detrusor, the order of potency was oxybutynin ≥ fesoterodine > trospium > darifenacin whereas in mucosa, the order was trospium > oxybutynin > fesoterodine > darifenacin. The data for darifenacin and fesoterodine were significantly better fitted to a two site rather than a one site model. Although oxybutynin exhitied a very low Hill slope, binding was not resolved into more than one site. Fesoterodine demonstrated high affinity binding (35% high affinity sites) in mucosal membranes but not in detrusor membranes. The high affinity component of darifenacin binding to mucosa and detrusor membranes represented 21% and 24% of total binding sites, respectively, with affinities corresponding to those reported for darifenacin binding to cloned human M3 receptors (cited in ref. 1). The high affinity binding of darifenacin to mucosal membranes demonstrated affinity corresponding to that reported at either M3 or M5 receptors. Interpretation of results One important finding of this study was that oxybutynin and fesoterodine were able to compete with equal affinity for [3H]QNB for binding to muscarinic receptors on both mucosa and detrusor membranes. However, trospium and darifenacin appeared to have different affinities in the two regions, although this finding would need confirmation. Receptor subtypes present in the human detrusor are 70% M2, 20% M3 and 10% M1, whereas in mucosa receptors were predominantly M2 with lower expression of M1, M3 and M5 (1). These results, together with the reported ability of muscarinic antagonists to influence the symptom of urgency, raise the possibility that mucosal muscarinic receptors may represent a novel site of action for muscarinic antagonists.
Concluding message To our knowledge, this is the first demonstration that antimuscarinic agents currently being used to treat patients bind with high affinity to the muscarinic receptors in the mucosa as well as detrusor. This finding reinforces the concept that antimuscarinic drugs interact with receptors in the human urothelium and/or lamina propria as well as in detrusor.
